Development and production of [18F]-DCFPyL, a PSMA-based radiotracer to support recurring prostate cancer PET clinical studies

This project that aims to develop and establish the production and analyses of a radioactive product at the CRCHUM Radiochemistry and Cyclotron laboratory for future use in human clinical trials using an imaging methodology called positron emission tomography (PET). This PET probe allows for the detection and measurement of Prostate-Specific Membrane Antigen (PSMA), a protein that is overexpressed in prostate cancer tissue and metastases derived from it. Using methods developed by others, we will synthesize the two compounds required for the production of this probe. A method allowing for the production of the final labeled product ([18F]-DCFPyl) from the two compounds will be adapted from previous publications and developed at the CRCHUM Radiochemistry and Cyclotron laboratory. The appropriate production, quality control tests and the development of standardized operating procedures will be completed to enable the submission of a Clinical Trial Application to Health Canada, which will allow for the use of this radioactive probe in human clinical PET imaging trials.

Faculty Supervisor:

Cynthia Menard;Jean DaSilva

Student:

Partner:

Institut du cancer de Montréal

Discipline:

Life Sciences

Sector:

Other services (except public administration); Professional, scientific and technical services

University:

Université de Montréal

Program: